CDKN2A and neoplasm: The RB pathway was considered disrupted in a tumor if one of the following events occurred: 1) RB1 mutation/homozygous deletion/underexpression; 2) CDKN2A mutation/homozygous deletion/underexpression; or 3) CCND1 overexpression.